Our goal is to have a clinical trial option available for patients at every stage of disease. We offer a range of clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.
Featured Clinical Trials
Newly-Diagnosed CLL
22-303: MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Principal Investigator: Matthew Davids, MD, MMSc
Relapsed/Refractory CLL
21-279: A phase 2 trial of zanubrutinib and venetoclax in previously treated CLL/SLL patients
Principal Investigator: Inhye Ahn, MD
20-415: SAVE (Safe Accelerated Venetoclax Escalation): A phase 1b study of venetoclax monotherapy with accelerated dose ramp-up in patients with CLL
Principal Investigator: Jennifer Crombie, MD
18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Principal Investigator: Matthew Davids, MD, MMSc
Richter’s Syndrome
23-429: A phase 2 study of glofitamab as monotherapy or in combination with polatuzumab vedotin or atezolizumab in Richter's transformation
Principal Investigator: Matthew Davids, MD, MMSc
18-089: A phase 1/2 study of duvelisib and venetoclax in patients with relapsed or refractory chronic lymphocytic lymphoma or small lymphocytic lymphoma (includes Richter's syndrome cohort)
Principal Investigator: Matthew Davids, MD, MMSc
16-596: CRC043: A phase 2 study of venetoclax in combination with R-CHOP for the therapy of patients with Richter’s syndrome
Principal Investigator: Matthew Davids, MD, MMSc
Learn more about clinical trials for CLL patients.
Translational Science
Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:
- Examining genetic material of a variety of CLLs in order to identify genetic changes that cause CLL
- Studying functional response of CLL cells to novel agent therapies to predict response to therapy and identify novel resistance mechanisms
- Providing CLL samples to a large network of collaborators who are working to better understand how CLL develops and how we can best target it with the goal of finding a cure